FDA approves new Alzheimer’s treatment, donanemab from Eli Lilly
The Food and Drug Administration approved a new Alzheimer’s treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing…
FDA approves Alzheimer’s drug donanemab after months of delay
The Food and Drug Administration granted approval Tuesday to a closely watched Alzheimer’s drug, concluding that the benefits of modestly slowing the progression of the devastating disease outweigh its risks,…
FDA approves Eli Lilly’s Alzheimer’s drug that slows memory decline
The Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities…
In Alzheimer’s breakthrough, researchers identify ‘protective gene’ that delays disease in high-risk family
{{#rendered}} {{/rendered}} A significant Alzheimer’s study is shedding new light on a protective gene that appears to delay the disease in those destined to develop it. Researchers from two Mass…
Alzheimer’s gene unlocks potential key to delaying disease
Researchers have discovered a rare genetic trait that could delay the onset of Alzheimer’s in people who face an overwhelming risk of developing the mind-robbing disease. A study published Wednesday…
Rare gene mutation helps people resist Alzheimer’s disease
In 2019, researchers announced the discovery of an unusually resilient person — a Colombian woman who carried a ticking time bomb in her genes that should have triggered an aggressive,…
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
CNN — On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the…
Alzheimer’s drug donanemab gets FDA advisory committee’s green light : Shots
An advisory committee to the Food and Drug Administration has recommended that the federal agency approve Alzheimer’s drug donanemab. Andrew Harnik/AP hide caption toggle caption Andrew Harnik/AP Advisors to the…
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
A committee of independent advisers to the Food and Drug Administration voted unanimously on Monday that the benefits outweigh the risks of the newest experimental drug for Alzheimer’s disease. Alzheimer’s…
FDA advisors recommend Eli Lilly Alzheimer’s drug donanemab
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the…